Biotech Buyside out of Undergrad?

I'm a freshman at one of the top STEM schools, which isn't really a target for finance outside of Quant. My background is in Bioengineering and CompBio, with a lot of research experience, and upcoming publications. 

I have noticed that the alums from my school in the biotech buyside were solely PhD's or MD/PhD's and none were undergrads. 

Do I have a chance of breaking into the biotech buy-side out of undergrad? Could I prove myself to funds with my past research and knowledge of the biotech space? Or must I pursue an MD, PhD, or go into IB/ER or Consulting, before making the transition? Thanks!

4 Comments
 
Most Helpful

It is definitely possible, Blackstone has a Life Sciences Group in Boston that does hire analysts. Another firm is Healthcare Royalty Partners. It really depends on what you want to do LT, as with Biotech investing, it can be super niche and cause you look at royalties on drugs it’s all about predicting the TAM/Market Opportunity forecasting top line correct and not wholesome modelling exercises. But a background like yours is definitely appreciated and would urge to at least look into possible seats in an economy like this where having an edge can really make the difference in securing offers. Good luck!

 

Doloribus eveniet vel sit magnam odio hic. Voluptas quaerat unde sit dolore vel eum at. Reiciendis illo quaerat ex maxime dolorem. Assumenda voluptatibus magnam incidunt illo et. Corporis eos quia ut eos modi praesentium non officia. Aut dolores quo voluptatem rerum. Sit dolor veniam ut eaque in unde.

Quis neque et pariatur tempore id temporibus architecto ut. Et vitae eveniet odio non voluptatem deserunt. Incidunt debitis quia voluptates qui. Et aspernatur autem consequuntur.

Vel neque ad velit quos eum ut sequi. Eos exercitationem perferendis autem molestias soluta laborum quibusdam. Ab repudiandae minus inventore nostrum.

Qui architecto ducimus ducimus id maiores quas. Tenetur possimus iure et tempore aut enim et minus. Aut architecto assumenda dolores illum quia velit. Est ut omnis adipisci adipisci suscipit qui. Nesciunt nihil consequatur iste voluptatem reiciendis illo at sed. Libero pariatur quis iure animi temporibus.

Career Advancement Opportunities

June 2026 Hedge Fund

  • Point72 99.0%
  • D.E. Shaw 98.1%
  • Citadel Investment Group 97.1%
  • AQR Capital Management 96.2%
  • Magnetar Capital 95.2%

Overall Employee Satisfaction

June 2026 Hedge Fund

  • Magnetar Capital 99.0%
  • Millennium Partners 98.1%
  • D.E. Shaw 97.1%
  • Blackstone Group 96.1%
  • Citadel Investment Group 95.1%

Professional Growth Opportunities

June 2026 Hedge Fund

  • AQR Capital Management 99.1%
  • Point72 98.1%
  • D.E. Shaw 97.2%
  • Citadel Investment Group 96.2%
  • Magnetar Capital 95.3%

Total Avg Compensation

June 2026 Hedge Fund

  • Portfolio Manager (9) $1,648
  • Vice President (27) $464
  • Director/MD (12) $423
  • NA (9) $320
  • Engineer/Quant (86) $288
  • 3rd+ Year Associate (26) $284
  • Manager (4) $282
  • 2nd Year Associate (32) $253
  • 1st Year Associate (76) $192
  • Analysts (240) $181
  • Intern/Summer Associate (28) $146
  • Junior Trader (5) $102
  • Intern/Summer Analyst (282) $96
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”